Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis.
Seidel C, Schaefers C, Connolly EA, Weickhardt A, Grimison P, Wong V, De Giorgi U, Hentrich M, Zschäbitz S, Ochsenreither S, Vincenzi B, Oing C, Bokemeyer C, Engel N, Alsdorf W, Tran B. Seidel C, et al. Among authors: tran b. ESMO Open. 2024 May;9(5):103449. doi: 10.1016/j.esmoop.2024.103449. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744098 Free PMC article.
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA, Willson K, Vincent AD, Tamjid B, Lee M, Bergin A, Gan C, Campbell A, Stewart J, Pezaro C, Tran B, Weickhardt AJ. Hamid AA, et al. Among authors: tran b. Asia Pac J Clin Oncol. 2018 Oct;14(5):e399-e404. doi: 10.1111/ajco.12840. Epub 2018 Jan 10. Asia Pac J Clin Oncol. 2018. PMID: 29318740
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A, Anton A, Shapiro J, Wong S, Azad A, Kwan E, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua AM, Pook D, Gibbs P, Tran B, Weickhardt A. Schmidt A, et al. Among authors: tran b. Asia Pac J Clin Oncol. 2021 Feb;17(1):36-42. doi: 10.1111/ajco.13447. Epub 2020 Sep 24. Asia Pac J Clin Oncol. 2021. PMID: 32970925
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.
Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Del Muro XG, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL, Sweeney CJ, Connors JM. Fankhauser CD, et al. Among authors: tran b. Eur Urol Focus. 2021 Sep;7(5):1130-1136. doi: 10.1016/j.euf.2020.09.017. Epub 2020 Oct 6. Eur Urol Focus. 2021. PMID: 33032968 Free article.
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours.
Sarkar S, Tran B, Horvath L, Lam M, Savas P, Grimison P, Whittle JR, Kuo JC, Signal N, Edmonds D, Hogg P, Rischin D, Desai J, Hamilton A. Sarkar S, et al. Among authors: tran b. Cancer Chemother Pharmacol. 2021 May;87(5):613-620. doi: 10.1007/s00280-020-04225-7. Epub 2021 Jan 26. Cancer Chemother Pharmacol. 2021. PMID: 33496801 Clinical Trial.
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).
Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C. Seidel C, et al. Among authors: tran b. World J Urol. 2021 Sep;39(9):3407-3414. doi: 10.1007/s00345-021-03635-3. Epub 2021 Mar 8. World J Urol. 2021. PMID: 33683412 Free PMC article.
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, Lorch A, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E, Chovanec M, Fankhauser C, Stark D, Grimison P, Necchi A, Tran B, Heidenreich A, Shamash J, Sternberg CN, Vaughn DJ, Duran I, Bokemeyer C, Patrikidou A, Cathomas R, Assele S, Gillessen S; International Germ Cell Cancer Classification Update Consortium. Beyer J, et al. Among authors: tran b. J Clin Oncol. 2021 May 10;39(14):1553-1562. doi: 10.1200/JCO.20.03292. Epub 2021 Mar 17. J Clin Oncol. 2021. PMID: 33729863 Free PMC article.
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Semira MC, Gibbs P, Tran B, Pezaro C. Anton A, et al. Among authors: tran b. Eur J Cancer. 2021 Nov;157:485-492. doi: 10.1016/j.ejca.2021.06.005. Epub 2021 Jul 31. Eur J Cancer. 2021. PMID: 34344533
1,486 results